Investors can speculate about the future of a stock by watching how its insiders buy and sell stocks. Puma Biotechnology Inc shares valued at $31,192 were purchased by NOUGUES MAXIMO F on Jan 02 ’25. At $3.05 per share, NOUGUES MAXIMO F acquired 10,227 shares.
Also, Ludwig Jeffrey Jerome purchased 9,437 shares, netting a total of over 28,783 in proceeds.
Before that, HUNT DOUGLAS M had added 8,633 shares to its account. In a trade valued at $26,331, the Officer bought Puma Biotechnology Inc shares for $3.05 each.
As published in a research note from Citigroup on September 28, 2021, Puma Biotechnology Inc [PBYI] has been rated up from a Neutral to a Buy and the price target has been revised to $11. As of October 08, 2019, Goldman has decreased its “Neutral” rating to a “Sell” for PBYI. Earlier on May 10, 2019, Citigroup downgraded its rating. Their new recommendation was “a Neutral” for PBYI stock which previously was a “a Buy”.
Analyzing PBYI Stock Performance
During the last five days, there has been a surge of approximately 3.31%. Over the course of the year, Puma Biotechnology Inc shares have jumped approximately 2.30%. Shares of the company reached a 52-week high of $3.37 on 01/02/25 and a 52-week low of $3.08 on 01/02/25. A 50-day SMA is recorded $2.97, while a 200-day SMA reached $3.51. Nevertheless, trading volume fell to 0.68 million shares from 0.68 million shares the previous day.
Support And Resistance Levels for Puma Biotechnology Inc (PBYI)
According to the 24-hour chart, there is a support level at 3.01, which, if violated, would cause prices to drop to 2.90. In the upper region, resistance lies at 3.30. The next price resistance is at 3.48. RSI (Relative Strength Index) is 55.35 on the 14-day chart, showing neutral technical sentiment. Moving Average Convergence Divergence (MACD) is at 0.14, which suggests the price will decrease in the coming days. Percent R is at 39.39%, indicating low price movement. Stochastics %K at holding indicates that the stock is to be held.
